Acquisition further extends Rocket’s leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathyCRANBURY, N.J. (BUSINESS WIRE) Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainabl.
Rocket Pharmaceuticals Completes Acquisition of Renovacor streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
For the readers interested in the stock health of Rocket Pharmaceuticals Inc. (RCKT). It is currently valued at $17.23. When the transactions were called off in the previous session, Stock hit the highs of $17.575, after setting-off with the price of $17.33. Company’s stock value dipped to $16.54
CRANBURY, N.J. (BUSINESS WIRE) Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced today that it has commenced an underwritten publi.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.